📣 VC round data is live. Check it out!

Black Diamond Therapeutics Valuation Multiples

Discover Black Diamond Therapeutics' revenue and EBITDA valuation multiples and investment history, alongside public comparables like Fractyl Health, Outlook Therapeutics, XSpray Pharma, Faron Pharmaceuticals and more.

Black Diamond Therapeutics Overview

About Black Diamond Therapeutics

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.


Founded

2016

HQ

United States

Employees

24

Financials (LTM)

Revenue: $43M
EBITDA: ($11M)

EV

$25M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Black Diamond Therapeutics Financials

Black Diamond Therapeutics reported last 12-month revenue of $43M and negative EBITDA of ($11M).

In the same LTM period, Black Diamond Therapeutics generated $43M in gross profit, ($11M) in EBITDA losses, and had net loss of ($4M).

Revenue (LTM)


Black Diamond Therapeutics P&L

In the most recent fiscal year, Black Diamond Therapeutics reported revenue of $70M and EBITDA of $20M.

Black Diamond Therapeutics is profitable as of last fiscal year, with EBITDA margin of 29% and net margin of 32%.

See analyst estimates for Black Diamond Therapeutics
LTMLast FY202320242025202620272028
Revenue$43M$70M--$70M
Gross Profit$43M---$70M
Gross Margin100%---100%
EBITDA($11M)$20M($86M)($78M)$20M
EBITDA Margin(25%)29%--29%
EBIT Margin(24%)28%--28%
Net Profit($4M)$22M($82M)($70M)$22M
Net Margin(9%)32%--32%

Financial data powered by Morningstar, Inc.

Black Diamond Therapeutics Stock Performance

Black Diamond Therapeutics has current market cap of $125M, and enterprise value of $25M.

Market Cap Evolution


Black Diamond Therapeutics' stock price is $2.18.

Black Diamond Therapeutics share price decreased by 1.8% in the last 30 days, and by 12.1% in the last year.

Black Diamond Therapeutics has an EPS (earnings per share) of $0.39.

See more trading valuation data for Black Diamond Therapeutics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$25M$125M-4.0%-1.8%2.3%-12.1%$0.39

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Black Diamond Therapeutics Valuation Multiples

Black Diamond Therapeutics trades at 0.6x EV/Revenue multiple, and (2.2x) EV/EBITDA.

See NTM and 2027E valuation multiples for Black Diamond Therapeutics

EV / Revenue (LTM)


Black Diamond Therapeutics Financial Valuation Multiples

As of June 3, 2026, Black Diamond Therapeutics has market cap of $125M and EV of $25M.

Black Diamond Therapeutics has a P/E ratio of (31.7x).

LTMLast FY202320242025202620272028
EV/Revenue0.6x0.4x--0.4x
EV/EBITDA(2.2x)1.2x(0.3x)(0.3x)1.2x
EV/EBIT(2.3x)1.2x(0.3x)(0.3x)1.2x
EV/Gross Profit0.6x---0.4x
P/E(31.7x)5.6x(1.5x)(1.8x)5.6x
EV/FCF-0.8x(0.4x)(0.4x)0.8x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Black Diamond Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Black Diamond Therapeutics Margins & Growth Rates

Black Diamond Therapeutics decreased revenue by 90% and EBITDA by 332% in the last fiscal year.

In the most recent fiscal year, Black Diamond Therapeutics reported EBITDA margin of 29% and net margin of 32%.

See estimated margins and future growth rates for Black Diamond Therapeutics

Black Diamond Therapeutics Margins

Last FY20252026202720282029
Gross Margin-100%100%
EBITDA Margin29%29%(657%)
EBIT Margin28%28%(621%)
Net Margin32%32%(560%)
FCF Margin42%42%-

Black Diamond Therapeutics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(90%)--(90%)
Gross Profit Growth---(90%)
EBITDA Growth(332%)(9%)(126%)(332%)
EBIT Growth(323%)(9%)(125%)(323%)
Net Profit Growth(279%)(15%)(132%)(279%)
FCF Growth-(7%)(148%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Black Diamond Therapeutics Operational KPIs

Black Diamond Therapeutics' revenue per employee in the last FY averaged $2.9M, while opex per employee averaged $2.1M for the same period.

Black Diamond Therapeutics' Rule of 40 is (747%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Black Diamond Therapeutics' Rule of X is (881%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Black Diamond Therapeutics
LTMLast FY2025202620272028
Rule of 40(116%)(747%)-
Bessemer Rule of X(252%)(881%)-
Revenue per Employee-$2.9M-
Opex per Employee-$2.1M-
G&A Expenses to Revenue43%26%24%
R&D Expenses to Revenue76%48%48%
Opex to Revenue-72%72%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Black Diamond Therapeutics Competitors

Black Diamond Therapeutics competitors include Fractyl Health, Outlook Therapeutics, XSpray Pharma, Faron Pharmaceuticals, Bioxyne, Orient Europharma Co, Naturland Holding, Cognition Therapeutics, vTv Therapeutics and NeOnc.

Most Black Diamond Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Fractyl Health--(1.3x)(1.4x)
Outlook Therapeutics101.5x12.7x(2.3x)-
XSpray Pharma176.1x26.8x(7.9x)(5.9x)
Faron Pharmaceuticals364.0x629.7x(6.0x)(5.8x)
Bioxyne6.0x-37.7x-
Orient Europharma Co1.1x-(4375.9x)-
Naturland Holding6.4x-22.1x-
Cognition Therapeutics--(3.8x)-

This data is available for Pro users. Sign up to see all Black Diamond Therapeutics competitors and their valuation data.

Start Free Trial

Black Diamond Therapeutics VC Funding History

Before going public, Black Diamond Therapeutics raised $197M in total equity funding, across 4 rounds.


Black Diamond Therapeutics Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Dec-19Series CBoxer Capital$85M--
Jan-19Series BBoxer Capital; New Enterprise Associates; RA Capital Management$85M-Black Diamond Therapeutics is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies focused on targeting oncogenic driver mutations. The company was founded by David M. Epstein, Ph.D. and Elizabeth Buck, Ph.D., and beginning in 2017 partnered with Versant Ventures to build its Mutation-Allostery-Pharmacology (MAP) platform and chemistry discovery engine. The company exited stealth mode in late 2018 with a $20 million Series A financing. In January 2019, Black Diamond closed an $85 million Series B financing led by Versant Ventures. By December 2019, the company had completed an oversubscribed $85 million Series C financing led by Boxer Capital of the Tavistock Group, bringing total capital raised to $194 million since founding. The Series C proceeds were designated to support company growth and advance development of lead product candidates targeting EGFR and HER2, with plans to initiate a combined Phase 1/2 clinical trial of BDTX-189 in the first half of 2020. The company submitted an IND for BDTX-189 in November 2019 and received FDA clearance in December 2019. Black Diamond was also developing a preclinical candidate for glioblastoma treatment designed to be brain penetrant. The company went public in 2020, listing on Nasdaq under ticker BDTX.
Dec-18Series AVersant Ventures$20M-Black Diamond Therapeutics emerged from stealth in December 2018 with a $20 million Series A financing exclusively from Versant Ventures. The company develops small molecule kinase inhibitors targeting allosteric mutant oncogenes using its MAP (Mutation-Allostery-Pharmacology) platform. This initial funding supported the creation of chemical leads, target validation, and advancement of drug candidates focused on EGFR and HER2 mutations. Following the Series A, Black Diamond quickly raised additional capital, including an $85 million Series B shortly after and nearly $200 million in total follow-on private financings. These funds enabled pipeline development for orally available, potent, and selective inhibitors. The company prepared to advance multiple candidates into clinical trials, with its lead program BDTX-189 receiving FDA IND clearance in December 2019. In January 2020, Black Diamond completed an IPO on NASDAQ, raising $201 million by selling 10.6 million shares. This milestone, just over a year after the Series A, highlighted rapid progress from Versant's Ridgeline Discovery Engine initiative. The firm has backed numerous biotech startups, with Black Diamond as its first Ridgeline-launched company achieving public status. The company, based in Cambridge, Massachusetts, continued preclinical work on additional programs, including brain-penetrant EGFR inhibitors for glioblastoma.
Mar-17Series A-$7M-Black Diamond Therapeutics had its first funding on 3/28/2017 with Versant Ventures listed as an investor. The company raised a total of $191M over 6 rounds prior to its IPO, with subsequent rounds including a Series A of $20M in January 2018 and a Series B of $85M in December 2018. Black Diamond Therapeutics is a precision oncology company developing small molecule therapies targeting oncogenic mutations using its Mutation-Allostery-Pharmacology (MAP) platform.

Investments by Black Diamond Therapeutics

Black Diamond Therapeutics has invested in 1 company to date.

Latest investment by Black Diamond Therapeutics was on December 12th 2022. Black Diamond Therapeutics invested in Launchpad Therapeutics in their $30M Series A round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Black Diamond Therapeutics

Launchpad Therapeutics
Description
Launchpad Therapeutics is a Boston-based biotechnology firm specializing in precision oncology through engineered antibodies. The company develops T cell engager antibodies targeting solid tumors, including platforms for conditional activation to minimize toxicity. Founded in 2021, it raised Series A funding from investors like ARCH Venture Partners and Takeda Ventures. Launchpad Therapeutics advances candidates like LP-284 into clinical trials for difficult-to-treat cancers such as pancreatic and colorectal.
HQ CountryUnited States
HQ City
San Francisco, CA
Deal Date12 Dec 2022
RoundSeries A
Raised$30M
InvestorsBlack Diamond Therapeutics; New Enterprise Associates; Versant Ventures
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Black Diamond Therapeutics investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Black Diamond Therapeutics

When was Black Diamond Therapeutics founded?Black Diamond Therapeutics was founded in 2016.
Where is Black Diamond Therapeutics headquartered?Black Diamond Therapeutics is headquartered in United States.
How many employees does Black Diamond Therapeutics have?As of today, Black Diamond Therapeutics has over 24 employees.
Who is the CEO of Black Diamond Therapeutics?Black Diamond Therapeutics' CEO is Mark A. Velleca.
Is Black Diamond Therapeutics publicly listed?Yes, Black Diamond Therapeutics is a public company listed on Nasdaq.
What is the stock symbol of Black Diamond Therapeutics?Black Diamond Therapeutics trades under BDTX ticker.
When did Black Diamond Therapeutics go public?Black Diamond Therapeutics went public in 2020.
Who are competitors of Black Diamond Therapeutics?Black Diamond Therapeutics main competitors include Fractyl Health, Outlook Therapeutics, XSpray Pharma, Faron Pharmaceuticals, Bioxyne, Orient Europharma Co, Naturland Holding, Cognition Therapeutics, vTv Therapeutics, NeOnc.
What is the current market cap of Black Diamond Therapeutics?Black Diamond Therapeutics' current market cap is $125M.
What is the current revenue of Black Diamond Therapeutics?Black Diamond Therapeutics' last 12 months revenue is $43M.
What is the current revenue growth of Black Diamond Therapeutics?Black Diamond Therapeutics revenue growth (NTM/LTM) is (91%).
What is the current EV/Revenue multiple of Black Diamond Therapeutics?Current revenue multiple of Black Diamond Therapeutics is 0.6x.
Is Black Diamond Therapeutics profitable?No, Black Diamond Therapeutics is not profitable.
What is the current EBITDA of Black Diamond Therapeutics?Black Diamond Therapeutics has negative EBITDA and is not profitable.
What is Black Diamond Therapeutics' EBITDA margin?Black Diamond Therapeutics' last 12 months EBITDA margin is (25%).
What is the current EV/EBITDA multiple of Black Diamond Therapeutics?Current EBITDA multiple of Black Diamond Therapeutics is (2.2x).
How many companies Black Diamond Therapeutics has acquired to date?Black Diamond Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Black Diamond Therapeutics has invested to date?As of June 2026, Black Diamond Therapeutics has invested in 1 company.
What was the last Black Diamond Therapeutics investment?On 12th December 2022 Black Diamond Therapeutics invested in Launchpad Therapeutics, participating in a $30M Series A round, alongside New Enterprise Associates and Versant Ventures.
In what companies Black Diamond Therapeutics invested in?Black Diamond Therapeutics invested in Launchpad Therapeutics.

See public comps similar to Black Diamond Therapeutics

Lists including Black Diamond Therapeutics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial